Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1998 Nov;20(6):457-9.

[Percutaneous transfemoral arterial implantation of drug delivery system for arterial infusion therapy of advanced primary hepatic carcinoma]

[Article in Chinese]
K Zhu  1 , G Hu, W Liang
Affiliations
  • PMID: 10920945
Clinical Trial

[Percutaneous transfemoral arterial implantation of drug delivery system for arterial infusion therapy of advanced primary hepatic carcinoma]

[Article in Chinese]
K Zhu et al. Zhonghua Zhong Liu Za Zhi. 1998 Nov.

Abstract

Objective: To study the efficiency of arterial infusion chemotherapy via drug delivery system (DDS) for advanced primary hepatic carcinoma.

Methods: Hepatic arterial infusion chemotherapy was performed in 82 cases of primary hepatic carcinoma with no indication for operation or transarterial embolism treatment. The patients were divided into 2 group as follows: (1) Group A: 42 patients were treated intra-arterially once every 1 or 2 weeks via implanted DDS. (2) Group B: 40 patients were treated through one bolus arterial infusion chemotherapy, once every month.

Results: The response rate (CR + PR) was 38.1% and 15.0% respectively in group A and B (P < 0.05); the 0.5-, 1- and 2- year survival rate was 61.9%, 28.6% and 9.5% respectively in group A, but 20%, 5%, 0% respectively in group B (P < 0.01); Liver, biliary, gastrointestinal and bone marrow toxicity in group A patients was greatly lower than those in group B patients.

Conclusion: Intermittent arterial infusion chemotherapy via DDS significantly improves survival and quality of life in patients with advanced primary hepatic carcinoma.

PubMed Disclaimer